[–] nanofortnight 7y ago ↗ Improper title.1. This is specifically about non-SCLC.2. This article is entirely about a downside to receiving PD-1/PDL-1 inhibitor biologics as immunotherapy; that approximately a third of patients develop HPD and should be switched to salvage chemotherapy as soon as this is noted.
1 comment
[ 2.8 ms ] story [ 14.8 ms ] thread1. This is specifically about non-SCLC.
2. This article is entirely about a downside to receiving PD-1/PDL-1 inhibitor biologics as immunotherapy; that approximately a third of patients develop HPD and should be switched to salvage chemotherapy as soon as this is noted.